Connaughton Bernadette
Halozyme Therapeutics, Inc. · Director
Connaughton Bernadette serves as a Director at Halozyme Therapeutics, Inc., where she is involved in strategic decisions within the healthcare sector. Her disclosed trading activity from May 2, 2025, to July 2, 2026, primarily reflects sale transactions, with a total of 12 sales recorded. The disclosed amounts range from $76.4K to $107.6K, highlighting her active engagement in managing her investment portfolio, particularly in Halozyme Therapeutics, Inc. (HALO) and Editas Medicine, Inc. (EDIT). Notably, the largest disclosed move involved a grant/exercise transaction valued at approximately $397.9K on May 7, 2026.
History Trades
| Company | Value | Action | Price | Last Price |
|---|---|---|---|---|
| $68k923 shares | SellSep 2, 2025 | $74.11 | $77.54 | |
| $219k3k shares | SellSep 2, 2025 | $73.62 | $77.54 | |
| $7.2k100 shares | SellSep 2, 2025 | $71.71 | $77.54 | |
| $38k500 shares | SellOct 1, 2025 | $75.70 | $77.54 | |
| $113k1.5k shares | SellOct 1, 2025 | $75.09 | $77.54 | |
| $137k2k shares | SellNov 10, 2025 | $68.48 | $77.54 | |
| $59k829 shares | SellDec 1, 2025 | $71.60 | $77.54 | |
| $141k2k shares | SellJan 5, 2026 | $70.25 | $77.54 | |
| $103k1.6k shares | SellMay 1, 2026 | $63.48 | $77.54 | |
| $108k1.6k shares | SellJun 1, 2026 | $66.21 | $77.54 |